Here in this study, our results demonstrated that HMGB1 is involved in the development and progression of AML not only by inhibiting cell apoptosis and promoting cell proliferation but also through acting as a negative regulator of myeloid differentiation, which provides more experimental evidence for conferring HMGB1 as a therapeutic target for AML. The gene discussed is HMGB1; the disease is acute myeloid leukemia.